Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.

Francesca CastagnoliSimon DoranJason LunnAnna MinchomMary O'BrienSanjay PopatChristina MessiouDow-Mu Koh

Published in: PloS one (2022)

No significant differences were observed in the splenic volume of those showing clinical benefit versus those without clinical benefit to pembrolizumab treatment in NSCLC patients. CT splenic volume cannot be used as a potentially simple biomarker of response to immunotherapy.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
advanced non small cell lung cancer
chronic kidney disease
computed tomography
patient reported outcomes
image quality
dual energy
tyrosine kinase